Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28327531 | 0.98 | NPC1 (0.53) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Hydrazine SCHEMBL27557475 | 0.96 | NPC1 (0.51) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Benzene SCHEMBL27557967 | 0.96 | NPC1 (0.53) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL6658073 | 0.84 | DYRK1A (0.60) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL29388659 | 0.83 | ALDH1A1 (0.50) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL4054554 | 0.83 | ALDH1A1 (0.50) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Hydrochloric Acid SCHEMBL27261649 | 0.79 | ALDH1A1 (0.47) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL31122229 | 0.79 | ALDH1A1 (0.43) | NPC1RAB9AKDM4ETDP1MEN1 | |
| SCHEMBL31214345 | 0.77 | DYRK1A (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL18042122 | 0.76 | DYRK1A (0.48) | NPC1RAB9AKDM4ETDP1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024103023-A2 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | VERALOX THERAPEUTICS (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024097846-A1 | ORAL PHARMACEUTICAL FORMULATIONS CONTAINING 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES | VERALOX THERAPEUTICS (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | claimed |
| WO-2024019959-A1 | COMPOSITIONS FOR MODULATING LIPOXYGENASE AND METHODS OF USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-25 | — | — | WO | claimed |
| EP-3054936-B1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2023-10-18 | — | — | EP | claimed |
| CN-115433072-B | Method for preparing aryl ketone by photocatalytic oxidation | 浙江工业大学 | 2023-08-08 | — | — | CN | claimed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | claimed |
| US-20230159516-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-05-25 | — | — | US | claimed |
| WO-2023043208-A1 | NOVEL 2-AMINOBENZOTHIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR | 부산대학교 산학협력단 | 2023-03-23 | — | — | WO | claimed |
| EP-4139280-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | Purdue Research Foundation (US) | 2023-03-01 | — | — | EP | claimed |
| CN-102781942-B | Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-23 | — | — | CN | claimed |
| US-9079911-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | claimed |
| WO-2015054662-A1 | 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2015-04-16 | — | — | WO | claimed |
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | claimed |
| US-8653263-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA (BE) | 2014-02-18 | — | — | US | claimed |
| CN-103333135-A | Synthesis technology of benthiavalicarb isopropyl | UNIV SHANGQIU NORMAL | 2013-10-02 | — | — | CN | claimed |
| EP-2491038-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | claimed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
| WO-1995011890-A1 | 6-FLUOROBENZOTHIAZOLES AND THEIR USE IN LIQUID CRYSTAL MIXTURES | MERCK PATENT GMBH (DE) | 1995-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | NPC1 1202/4885RAB9A 2680/4885KDM4E 454/4885 |
| US-20230159516-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | ACE2, ACE, SARS1 | NPC1 180/4885RAB9A 1275/4885KDM4E 3347/4885 |
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | NPC1 1202/4885RAB9A 2680/4885KDM4E 454/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | NPC1 1202/4885RAB9A 2680/4885KDM4E 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.